Welcome to our dedicated page for Biovie news (Ticker: BIVI), a resource for investors and traders seeking the latest updates and insights on Biovie stock.
BioVie, Inc. develops clinical-stage drug therapies for neurological and neurodegenerative diseases and advanced liver disease. Company news centers on bezisterim, also known as NE3107, an investigational oral small molecule studied in Parkinson’s disease, Alzheimer’s disease and Long COVID through its effects on neuroinflammation and insulin sensitivity.
Recurring updates include clinical-study enrollment and results planning, scientific-conference abstracts, key opinion leader events and investor presentations. BioVie also reports on BIV201, its orphan drug candidate for refractory ascites associated with liver cirrhosis, alongside corporate communications about pipeline progress and financing activity.
BioVie (NASDAQ:BIVI), a clinical-stage biopharma focused on neurological and neurodegenerative diseases, will host a live investor webinar on June 2, 2026 at 4:15 p.m. ET.
Management will discuss bezisterim (NE3107), late-stage drug candidate BIV201, clinical progress, safety data, and upcoming milestones, followed by a Q&A session.
BioVie (NASDAQ:BIVI) announced full enrollment of its ADDRESS-LC Phase 2 trial of bezisterim for neurological symptoms of Long COVID. The study is fully funded by a U.S. Department of War grant, with topline data targeted for late summer 2026.
ADDRESS-LC evaluates bezisterim’s proposed modulation of inflammatory pathways linked to neurocognitive and neuropsychiatric Long COVID symptoms such as fatigue, cognitive dysfunction, post-exertional malaise and sleep disturbance. There are currently no FDA-approved treatments for Long COVID.
BioVie (NASDAQ:BIVI) completed the last patient evaluation visit in its SUNRISE-PD Phase 2 trial of bezisterim in early-stage Parkinson’s disease, with topline data targeted for Q3 2026.
The study aims to evaluate motor and non-motor outcomes and inform Phase 3 registrational trial design.
BioVie (NASDAQ: BIVI) will host a virtual Key Opinion Leader event on May 7, 2026 at 2:00 PM ET to discuss bezisterim (NE3107) and the company’s Phase 2 study in Parkinson's disease ahead of topline data due in 2Q26.
The session features Suzanne de la Monte, MD, MPH, and company management, with a live Q&A. The event will review bezisterim’s mechanism of action and its preclinical and early clinical signals on inflammation and insulin resistance related to Parkinson’s pathology.
BioVie (NASDAQ: BIVI) announced that an abstract from its SUNRISE-PD study of bezisterim (NE3107) in early Parkinson’s disease was accepted for presentation at the American Academy of Neurology Annual Meeting in Chicago, April 18–22, 2026.
The poster, titled "A Study of NE3107 (Bezisterim) in Early Parkinson's Disease (SUNRISE-PD): Baseline Demographics and Characteristic," will be presented on Monday, April 20, 5:00–6:00 PM CT. Topline results from SUNRISE-PD are expected in mid‑2026. The AAN represents 44,000+ neurology professionals.
BioVie (NASDAQ: BIVI) announced an abstract acceptance for a poster presentation from its SUNRISE-PD study of bezisterim (NE3107) in early Parkinson’s disease at AD/PD 2026, March 17-21 in Copenhagen.
The poster, “Demographics and Baseline Characteristics of Participants in a Study of Bezisterim (SUNRISE-PD),” summarizes initial enrolled-patient data. Topline results are expected in mid-2026.
BioVie (NASDAQ: BIVI) will host an exclusive investor webinar on March 4, 2026 at 4:15 p.m. ET and a live Q&A with CEO Cuong Do. The presentation will review investigational drug bezisterim (NE3107) and orphan candidate BIV201, clinical progress, safety signals, and development plans.
Registration is free via RedChip and questions may be pre-submitted to BIVI@redchip.com or asked live.
BioVie (NASDAQ: BIVI) announced two abstracts on its lead candidate bezisterim (NE3107) were accepted for poster presentation at the 2026 American College of Psychiatrists annual meeting, Feb 18-22 in Bonita Springs, FL.
Both posters will be presented on February 18, 2026, covering bezisterim effects in Alzheimer’s disease and baseline characteristics from the Phase 2 Long COVID study (ADDRESS-LC).
BioVie (NASDAQ: BIVI) completed enrollment of 60 patients in its Phase 2 SUNRISE-PD trial testing bezisterim (NE3107) in early Parkinson’s disease patients not previously treated with carbidopa/levodopa. SUNRISE-PD uses a hybrid, decentralized design to improve access and flexibility for participants ages 41–80 diagnosed within the past four years. BioVie expects to analyze data and report topline results in 1H 2026. The company noted prior PD studies of bezisterim with levodopa/carbidopa showed symptom improvements and a favorable safety profile.
BioVie (NASDAQ: BIVI) invites investors to a live webinar on December 9, 2025 at 4:15 p.m. ET, hosted by RedChip Companies.
CEO Cuong Do will discuss bezisterim (NE3107) — an oral small molecule studied for inflammation and insulin resistance linked to Alzheimer’s, Parkinson’s, and Long COVID — and progress on BIV201, a late‑stage orphan candidate for refractory ascites. A live Q&A will follow; registration is free at the event link and questions can be pre‑submitted to BIVI@redchip.com.